Novo Nordisk A/S (NYSE:NVO) Receives $133.60 Consensus Target Price from Brokerages

Shares of Novo Nordisk A/S (NYSE:NVO) have been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $133.60.

NVO has been the topic of a number of research reports. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. BMO Capital Markets started coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. Finally, UBS Group started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 16th. They issued a “neutral” rating on the stock.

Novo Nordisk A/S Trading Up 2.2 %

Shares of NVO stock opened at $127.28 on Friday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.50 and a current ratio of 0.70. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The stock has a 50 day simple moving average of $127.33 and a two-hundred day simple moving average of $113.50. The company has a market cap of $571.17 billion, a P/E ratio of 43.89, a PEG ratio of 1.93 and a beta of 0.43.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Pacific Center for Financial Services lifted its holdings in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the last quarter. First PREMIER Bank bought a new position in Novo Nordisk A/S in the first quarter worth $25,000. Bell Investment Advisors Inc increased its stake in shares of Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company’s stock valued at $26,000 after purchasing an additional 127 shares in the last quarter. CNB Bank purchased a new position in Novo Nordisk A/S during the fourth quarter valued at $26,000. Finally, Dixon Mitchell Investment Counsel Inc. purchased a new stake in Novo Nordisk A/S during the 1st quarter valued at about $26,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.